Ambulero, Inc. is a cell and gene therapy spin-out from the University of Miami, dedicated to developing innovative therapies for vascular diseases. The company’s core mission is to advance regenerative medicine by leveraging its proprietary technology to deliver the adhesion molecule E-selectin through various cell and synthetic vector platforms. Ambulero focuses on creating first-in-class treatments that target vascular conditions, aiming to improve patient outcomes and address unmet medical needs in this critical healthcare sector.

Notable individuals affiliated with Ambulero include experts from the University of Miami who have contributed to its foundational research. The company has attracted attention from key investors interested in pioneering advancements in regenerative medicine. Ambulero's significant achievements include the development of its unique platform technology and progress in preclinical trials, positioning it as a promising player in the biotech industry. The overall impact of Ambulero lies in its potential to revolutionize treatments for vascular diseases, offering hope to patients with limited therapeutic options.